Description
Pantor-20/Pantor-40:Β Mechanism of Action: Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus.
Pharmacokinetics:Β Pantor-20/Pantor-40: Pantoprazole sodium delayed-release tablets are prepared as enteric-coated tablets so that absorption of pantoprazole begins only after the tablet leaves the stomach.Β Pantoprazole does not accumulate, and its pharmacokinetics are unaltered with multiple daily dosing. Following oral or intravenous administration, the serum concentration of pantoprazole declines biexponentially, with a terminal elimination half-life of approximately one hour.
Pantor-20/Pantor-40:Β Pantoprazole (Pantor-20/Pantor-40) Enteric-Coated tablets should be swallowed whole, with or without food in the stomach. If patients are unable to swallow a 40 mg tablet, two 20 mg tablets may be taken. Concomitant administration of antacids does not affect the absorption of Pantoprazole sodium enteric-coated tablets.
Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD):Β Adults: 40 mg once daily up to 8 weeks*.
Children (5 years and older): >15 kg to <40 kg: 20 mg once daily for up to 8 weeks.
>40 kg: 40 mg.
* For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course may be considered.
